Article
Prior therapy defines mutation profiles in childhood cancer at relapse.
Nature - 1 Sept 2026
Layeghifard Mehdi, Díaz-Gay Marcos, Bergstrom Erik N, Mahendralingam Mathepan J, Light Nicholas, Blay Sasha, Nash Joshua O, Anderson Nathaniel D, Au Jessica N, Davidson Scott, Ballester Pedro L, Wen Timmy, Daud Syed Kashif, Edward Lisa-Monique, Ashiqul Islam S M, Khandekar Azhar, Otlu Burçak, Brunga Ledia, Hammad Rawan, Nassif Shimaa, Thacker Nirav H, Feltham Tara, Fuentes-Bolanos Noemi A, Wong-Erasmus Marie, Levine Max F, Miller Katherine E, Shukla Neerav N, Kinnaman Michael D, Glodzik Dominik, Portwine Carol, Millson Sabrina, Zorzi Alexandra P, Mikhail Mariam, Fernandez Conrad V, Wheaton Laura, Gundem Gunes, Kung Andrew L, Tabori Uri, Mayoh Chelsea, Papaemmanuil Elli, Cowley Mark J, Malkin David, Villani Anita, Alexandrov Ludmil B, Shlien Adam
Abstract excerpt
Children with cancer develop many short- and long-term side-effects of treatment1, but the amount of DNA damage associated with chemotherapy exposure is unclear2. Here we used mutational signatures to measure this damage using whole-genome-sequenced tumours from a multi-institutional cohort for which therapy dose and total exposure were uniformly collected3-5. Chemotherapy and radiotherapy were the only exogenous...
Read the complete abstract on PubMedTopics
- Child
- Humans